Basic Information

Gene symbol CTAG1B Synonyms CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 Type of gene protein-coding
Description cancer/testis antigen 1B

GTO ID GTC0375
Trial ID NCT03168438
Disease Neoplasm
Altered gene NY-ESO-1
Therapeutic/Target gene Target gene
TherapyTCR-T cell
Treatment Letetresgene autoleucel|GSK3377794|Lete-cel
HLAHLA-A*02:01|HLA-A*02:05|HLA-A*02:06
PhasePhase1
Recruitment statusTerminated
TitleOpen-Label Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma
Year2017
CountryUnited States
Company sponsorGlaxoSmithKline
Other ID(s)208470|ADP-0011-008|KEYNOTE-487
Vector information
Vectorlentivirus

Clinical Result

Cohort1: Letetresgene autoleucel
Administration route infusion
Dosage 1~5.6E9 cells
Donor type autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 1/3(CR); 2/3(SD)
Adverse reactions 2/3(Blood and lymphatic system disorders; Cardiac disorders)
References PMID: 36534160
Cohort2: Letetresgene autoleucel with pembrolizumab
Administration route infusion
Dosage 1~5.6E9 cells
Donor type autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 2/3(PR); 1/3(SD)
Adverse reactions 2/3(All-cause mortality); 2/4(Blood and lymphatic system disorders; Infections and infestations; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps)
References PMID: 36534160

Relationship Graph

Overview of Knowledge Graph